Skip to main content

NUEVA NANOHERRAMIENTA PARA EL TRATAMIENTO DEL NEUROBLASTOMA METASTASICO

PI20/00530

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON
Execution centre INSTITUTO DE INVESTIGACION HOSPITAL UNIVERSITARIO VALLE DE HEBRON (VHIR)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models

  • Masanas Jimenez, Marc
  • Masia Fandos, Nuria
  • Suarez Cabrera, Leticia
  • Olivan Riera, Mireia
  • Soriano Fernández, Aroa
  • Majem Cavaller, Blanca
  • Jimenez Jimenez, Carlos Gonzalo
  • Boloix Amenós, Ariadna
  • Toledano Martin, Ignasi
  • Navarro Jimenez, Alexandra
  • Sánchez de Toledo Codina, Josep
  • Roma Castanyer, Josep
  • Moreno Martín-Retortillo, Lucas
  • Gallego Melcón, Soledad
  • Segura Ginard, Miguel
  • Santamaria Margalef, Anna
  • Guillén Burrieza, Gabriela
Inhibidor de KIF11; Terapias dirigidas; Metástasis, Inhibidor de KIF11; Teràpies dirigides; Metàstasi, KIF11 inhibitor; Targeted therapies; Metastasis, In summary, our study provides a rationale for the future therapeutic integration in clinical trials of 4SC-205, an structurally distinct oral KIF11 inhibitor that shows potent antitumor activity in multiple preclinical neuroblastoma models and sensitizes neuroblastoma cells to standard chemotherapy and specific neuroblastoma-targeted therapies., The financial support for this research was provided by Instituto de Salud Calos III (PI20/00530 to Miguel F. Segura; PI20/01107 to Rosa Noguera; PI17/02248 and CPII18/00027 to Anna Santamaria; PI19/01320 to Alberto Villanueva); Ministerio de Educación, Cultura y Deporte (Grant no. FPU16/01099 to Marc Masanas). This work was also supported by the Asociación NEN (Nico contra el cancer infantil 2017–PVR00157).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Neuronal Differentiation-Related Epigenetic Regulator ZRF1 Has Independent Prognostic Value in Neuroblastoma but Is Functionally Dispensable In Vitro

  • Jimenez Jimenez, Carlos Gonzalo
  • Antonelli, Roberta
  • Masanas Jimenez, Marc
  • Soriano Fernández, Aroa
  • Devis-Jauregui, Laura
  • Camacho Soriano, Jessica
  • Magdaleno Cazon, Ainara
  • Hladun Alvaro, Raquel
  • Jubierre Zapater, Luz
  • Roma Castanyer, Josep
  • Sánchez de Toledo Codina, Josep
  • Moreno Martín-Retortillo, Lucas
  • Gallego Melcón, Soledad
  • Segura Ginard, Miguel
  • Guillén Burrieza, Gabriela
Epigenética; Diferenciación neuronal; Cáncer pediátrico, Epigenètica; Diferenciació neuronal; Càncer pediàtric, Epigenetics; Neuronal differentiation; Pediatric cancer, Neuroblastoma is a pediatric tumor of the peripheral nervous system that accounts for up to ~15% of all cancer-related deaths in children. Recently, it has become evident that epigenetic deregulation is a relevant event in pediatric tumors such as high-risk neuroblastomas, and a determinant for processes, such as cell differentiation blockade and sustained proliferation, which promote tumor progression and resistance to current therapies. Thus, a better understanding of epigenetic factors implicated in the aggressive behavior of neuroblastoma cells is crucial for the development of better treatments. In this study, we characterized the role of ZRF1, an epigenetic activator recruited to genes involved in the maintenance of the identity of neural progenitors. We combined analysis of patient sample expression datasets with loss- and gain-of-function studies on neuroblastoma cell lines. Functional analyses revealed that ZRF1 is functionally dispensable for those cellular functions related to cell differentiation, proliferation, migration, and invasion, and does not affect the cellular response to chemotherapeutic agents. However, we found that high levels of ZRF1 mRNA expression are associated to shorter overall survival of neuroblastoma patients, even when those patients with the most common molecular alterations used as prognostic factors are removed from the analyses, thereby suggesting that ZRF1 expression could be used as an independent prognostic factor in neuroblastoma., This work was funded by Instituto de Salud Carlos III (Grant no. CP16/00006, PI17/00564 and PI20/00530 to M.F Segura and MS17/00063 to D. Llobet-Navas); Asociación Española Contra el Cáncer (LABAE18009SEGU, LABAE19004LLOB); Generalitat de Catalunya AGAUR/European Social Fund (Grant no. 2017FI_B_00095 to C Jiménez); Asociación NEN; Joan Petit foundation; Asociación Pulseras Candela foundation; the #delhospitalalacatedral initiative led by Xavi Vallés; and the Rotary Clubs of Barcelona Eixample, Barcelona Diagonal, Santa Coloma de Gramanet, München-Blutenburg, Deutschland Gemeindienst, and others from Barcelona and its province.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Structural disruption of BAF chromatin remodeller impairs neuroblastoma metastasis by reverting an invasiveness epigenomic program

  • Jimenez Jimenez, Carlos Gonzalo
  • Antonelli, Roberta
  • Nadal-Ribelles, Mariona
  • Devis-Jauregui, Laura
  • Latorre Doménech, Pablo
  • Solé Serra, Carme
  • Masanas Jimenez, Marc
  • Molero Valenzuela, Adria
  • Soriano Fernández, Aroa
  • Sánchez de Toledo Codina, Josep
  • Llobet-Navas, David
  • Roma Castanyer, Josep
  • Posas, Francesc
  • de Nadal, Eulalia
  • Gallego Melcón, Soledad
  • Moreno Martín-Retortillo, Lucas
  • Segura Ginard, Miguel
Chromatin remodelling; Epigenetics; Metastasis, Remodelación de cromatina; Epigenética; Metástasis, Remodelació de cromatina; Epigenètica; Metàstasi, Background Epigenetic programming during development is essential for determining cell lineages, and alterations in this programming contribute to the initiation of embryonal tumour development. In neuroblastoma, neural crest progenitors block their course of natural differentiation into sympathoadrenergic cells, leading to the development of aggressive and metastatic paediatric cancer. Research of the epigenetic regulators responsible for oncogenic epigenomic networks is crucial for developing new epigenetic-based therapies against these tumours. Mammalian switch/sucrose non-fermenting (mSWI/SNF) ATP-dependent chromatin remodelling complexes act genome-wide translating epigenetic signals into open chromatin states. The present study aimed to understand the contribution of mSWI/SNF to the oncogenic epigenomes of neuroblastoma and its potential as a therapeutic target. Methods Functional characterisation of the mSWI/SNF complexes was performed in neuroblastoma cells using proteomic approaches, loss-of-function experiments, transcriptome and chromatin accessibility analyses, and in vitro and in vivo assays. Results Neuroblastoma cells contain three main mSWI/SNF subtypes, but only BRG1-associated factor (BAF) complex disruption through silencing of its key structural subunits, ARID1A and ARID1B, impairs cell proliferation by promoting cell cycle blockade. Genome-wide chromatin remodelling and transcriptomic analyses revealed that BAF disruption results in the epigenetic repression of an extensive invasiveness-related expression program involving integrins, cadherins, and key mesenchymal regulators, thereby reducing adhesion to the extracellular matrix and the subsequent invasion in vitro and drastically inhibiting the initiation and growth of neuroblastoma metastasis in vivo. Conclusions We report a novel ATPase-independent role for the BAF complex in maintaining an epigenomic program that allows neuroblastoma invasiveness and metastasis, urging for the development of new BAF pharmacological structural disruptors for therapeutic exploitation in metastatic neuroblastoma., This work was funded by Instituto de Salud Carlos III (CP16/00006, PI17/00564 and PI20/00530 to MFS and MS17/00063 to DL-N); Asociación Española Contra el Cáncer (LABAE18009SEGU to MFS, LABAE19004LLOB to DL-N, PROYE18010POSA to FP); Generalitat de Catalunya (2017FI_B_00095 to CJ, 2017SGR799 to FP and EdN; institutional funding through CERCA Programme); La Caixa Foundation (LCF/BQ/PR20/11770001 to MN-R); Spanish Ministry of Economy and Competitiveness (PID2021-124723NB-C21 to FP and PID2021-124723NB-C22 to EdN); Spanish Ministry of Science, Innovation and Universities (institutional funding through Centres of Excellence Severo Ochoa Award); State Research Agency (institutional funding through Unidad de Excelencia María de Maeztu, CEX2018-000792-M); and the Catalan Institution for Research and Advanced Studies (Academia awards to EdN and FP). Funding was also received from NEN association; Joan Petit foundation; Asociación Pulseras Candela foundation; and the Rotary Clubs of Barcelona Eixample, Barcelona Diagonal, Santa Coloma de Gramanet, München-Blutenburg, Deutschland Gemeindienst, and others from Barcelona and its province.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Engineering pH-Sensitive Stable Nanovesicles for Delivery of MicroRNA Therapeutics

  • Boloix Amenós, Ariadna
  • Feiner-Gracia, Natalia
  • Repetto, Javier
  • Pascarella, Rosa
  • Soriano Fernández, Aroa
  • Masanas Jimenez, Marc
  • Roma Castanyer, Josep
  • Sánchez de Toledo Codina, Josep
  • Gallego Melcón, Soledad
  • Segura Ginard, Miguel
  • Foradada Felip, Laia
  • Köber, Mariana
Nanovesicles; Neuroblastoma; Pediatric cancer, Nanovesículas; Neuroblastoma; Cáncer pediátrico, Nanovesícules; Neuroblastoma; Càncer pediàtric, MicroRNAs (miRNAs) are small non-coding endogenous RNAs, which are attracting a growing interest as therapeutic molecules due to their central role in major diseases. However, the transformation of these biomolecules into drugs is limited due to their unstability in the bloodstream, caused by nucleases abundantly present in the blood, and poor capacity to enter cells. The conjugation of miRNAs to nanoparticles (NPs) could be an effective strategy for their clinical delivery. Herein, the engineering of non-liposomal lipid nanovesicles, named quatsomes (QS), for the delivery of miRNAs and other small RNAs into the cytosol of tumor cells, triggering a tumor-suppressive response is reported. The engineered pH-sensitive nanovesicles have controlled structure (unilamellar), size (<150 nm) and composition. These nanovesicles are colloidal stable (>24 weeks), and are prepared by a green, GMP compliant, and scalable one-step procedure, which are all unavoidable requirements for the arrival to the clinical practice of NP based miRNA therapeutics. Furthermore, QS protect miRNAs from RNAses and when injected intravenously, deliver them into liver, lung, and neuroblastoma xenografts tumors. These stable nanovesicles with tunable pH sensitiveness constitute an attractive platform for the efficient delivery of miRNAs and other small RNAs with therapeutic activity and their exploitation in the clinics., The funding was received by Ministerio de Educación, Cultura y Deporte (Grant no. FPU16/01099), Ministerio de Economía, Industria y Competividad (Grants MAT2016-80820-R, MAT2016-80826-R and SAF2016-75241-R), the Ministry of Science and Innovation (MINECO) of Spain through grant PID2019-105622RB-I00, from Instituto de Salud Carlos III (Grant no. CP16/00006, PI17/00564, PI20/00530, DTS20/00018) (Co-funded by European Regional Development Fund/European Social Fund) “Investing in your future”), from the EuroNanoMed II platform through the NanoVax project, from CIBER-BBN through grant TAG-SMARTLY, Joan Petit Foundation, Asociación Matem Lo Bitxo and Asociación Española Contra el Cáncer (Grant no. LABAE18009SEGU), as well as, Generalitat de Catalunya through the Centres de Recerca de Catalunya (CERCA) programme and grant no. 2017-SGR-918, and from Agency for Management of University and Research Grants (AGAUR) (Grant no 2018LLAV0064 and SIFECAT IU68-010017). Furthermore, ICMAB-CSIC acknowledges support from the MINECO through the Severo Ochoa Programme for Centres of Excellence in R&D (SEV-2015-0496 and CEX2019-000917-S).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Structural disruption of BAF chromatin remodeller impairs neuroblastoma metastasis by reverting an invasiveness epigenomic program

  • Jiménez Jiménez, Carlos|||0000-0001-9219-3492
  • Antonelli, Roberta|||0000-0001-6884-7847
  • Nadal-Ribelles, Mariona|||0000-0003-3314-6711
  • Devis-Jauregui, Laura|||0000-0003-3736-3983
  • Latorre, Pablo|||0000-0003-1694-3663
  • Solé Serra, Carme|||0000-0003-4543-7401
  • Masanas, Marc|||0000-0002-2249-8554
  • Molero Valenzuela, Adrià|||0000-0002-0356-5299
  • Soriano, Aroa|||0000-0001-9659-1471
  • Sánchez de Toledo Codina, José|||0000-0002-1034-1920
  • Llobet Navas, David|||0000-0003-1443-7003
  • Roma, Josep|||0000-0001-7692-6123
  • Posas, Francesc|||0000-0002-4164-7076
  • de Nadal, Eulàlia|||0000-0003-0039-5607
  • Gallego, Soledad|||0000-0002-4712-9624
  • Moreno Martin Retortillo, Lucas|||0000-0002-0708-1670
  • Segura, Miguel F.|||0000-0003-0916-3618
Epigenetic programming during development is essential for determining cell lineages, and alterations in this programming contribute to the initiation of embryonal tumour development. In neuroblastoma, neural crest progenitors block their course of natural differentiation into sympathoadrenergic cells, leading to the development of aggressive and metastatic paediatric cancer. Research of the epigenetic regulators responsible for oncogenic epigenomic networks is crucial for developing new epigenetic-based therapies against these tumours. Mammalian switch/sucrose non-fermenting (mSWI/SNF) ATP-dependent chromatin remodelling complexes act genome-wide translating epigenetic signals into open chromatin states. The present study aimed to understand the contribution of mSWI/SNF to the oncogenic epigenomes of neuroblastoma and its potential as a therapeutic target. Functional characterisation of the mSWI/SNF complexes was performed in neuroblastoma cells using proteomic approaches, loss-of-function experiments, transcriptome and chromatin accessibility analyses, and in vitro and in vivo assays. Neuroblastoma cells contain three main mSWI/SNF subtypes, but only BRG1-associated factor (BAF) complex disruption through silencing of its key structural subunits, ARID1A and ARID1B, impairs cell proliferation by promoting cell cycle blockade. Genome-wide chromatin remodelling and transcriptomic analyses revealed that BAF disruption results in the epigenetic repression of an extensive invasiveness-related expression program involving integrins, cadherins, and key mesenchymal regulators, thereby reducing adhesion to the extracellular matrix and the subsequent invasion in vitro and drastically inhibiting the initiation and growth of neuroblastoma metastasis in vivo. We report a novel ATPase-independent role for the BAF complex in maintaining an epigenomic program that allows neuroblastoma invasiveness and metastasis, urging for the development of new BAF pharmacological structural disruptors for therapeutic exploitation in metastatic neuroblastoma.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models

  • Masanas, Marc|||0000-0002-2249-8554
  • Masiá, Nuria|||0000-0002-8352-2327
  • Suárez, Leticia|||0000-0002-3864-4616
  • Olivan, Mireia|||0000-0002-8464-0827
  • Soriano, Aroa|||0000-0001-9659-1471
  • Majem Cavaller, Blanca|||0000-0003-3613-0432
  • Devis-Jauregui, Laura|||0000-0003-3736-3983
  • Burgos-Panadero, Rebeca
  • Jiménez Jiménez, Carlos|||0000-0001-9219-3492
  • Rodriguez-Sodupe, Pau
  • Boloix, Ariadna|||0000-0002-1648-5589
  • Toledano, Ignasi|||0000-0003-0880-8904
  • Guillén, Gabriela|||0000-0001-5632-2672
  • Navarro, Alexandra
  • Llobet Navas, David|||0000-0003-1443-7003
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Sánchez de Toledo Codina, José|||0000-0002-1034-1920
  • Roma, Josep|||0000-0001-7692-6123
  • Noguera, Rosa
  • Moreno Martin Retortillo, Lucas|||0000-0002-0708-1670
  • Krauss, Rolf
  • Gallego, Soledad|||0000-0002-4712-9624
  • Santamaría Margalef, Anna|||0000-0001-6726-8990
  • Segura, Miguel F.|||0000-0003-0916-3618
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Neuronal Differentiation-Related Epigenetic Regulator ZRF1 Has Independent Prognostic Value in Neuroblastoma but Is Functionally Dispensable In Vitro

  • Jiménez Jiménez, Carlos|||0000-0001-9219-3492
  • Antonelli, Roberta|||0000-0001-6884-7847
  • Masanas, Marc|||0000-0002-2249-8554
  • Soriano, Aroa|||0000-0001-9659-1471
  • Devis-Jauregui, Laura|||0000-0003-3736-3983
  • Camacho, Jessica|||0000-0001-8018-8274
  • Magdaleno, Ainara|||0000-0002-2718-3244
  • Guillén, Gabriela|||0000-0001-5632-2672
  • Hladun, Raquel|||0000-0002-3191-1750
  • Jubierre Zapater, Luz
  • Llobet Navas, David|||0000-0003-1443-7003
  • Sánchez de Toledo Codina, José|||0000-0002-1034-1920
  • Moreno Martin Retortillo, Lucas|||0000-0002-0708-1670
  • Gallego, Soledad|||0000-0002-4712-9624
  • Segura, Miguel F.|||0000-0003-0916-3618
Neuroblastoma is the most common pediatric solid tumor occurring outside the brain, and it is thought to arise from cells that acquire errors during the normal process of embryonal development. Today, we know that embryonal development is regulated by epigenetics, a mechanism that determines which genes need to be expressed in each cell type and developmental step. Epigenetic errors, therefore, are considered contributory to the appearance and progression of tumors such as neuroblastoma. Here, we aimed at finding whether ZRF1, a known epigenetic regulator, could play a significant role in the aggressiveness of neuroblastoma. Our results suggest that ZRF1 does not seem to have any relevant function in neuroblastoma cells; however, the levels of this epigenetic regulator are related to the prognostic of neuroblastoma patients and could be used to predict their progression and improve the diagnosis. Neuroblastoma is a pediatric tumor of the peripheral nervous system that accounts for up to ~15% of all cancer-related deaths in children. Recently, it has become evident that epigenetic deregulation is a relevant event in pediatric tumors such as high-risk neuroblastomas, and a determinant for processes, such as cell differentiation blockade and sustained proliferation, which promote tumor progression and resistance to current therapies. Thus, a better understanding of epigenetic factors implicated in the aggressive behavior of neuroblastoma cells is crucial for the development of better treatments. In this study, we characterized the role of ZRF1, an epigenetic activator recruited to genes involved in the maintenance of the identity of neural progenitors. We combined analysis of patient sample expression datasets with loss- and gain-of-function studies on neuroblastoma cell lines. Functional analyses revealed that ZRF1 is functionally dispensable for those cellular functions related to cell differentiation, proliferation, migration, and invasion, and does not affect the cellular response to chemotherapeutic agents. However, we found that high levels of ZRF1 mRNA expression are associated to shorter overall survival of neuroblastoma patients, even when those patients with the most common molecular alterations used as prognostic factors are removed from the analyses, thereby suggesting that ZRF1 expression could be used as an independent prognostic factor in neuroblastoma.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Engineering pH-Sensitive Stable Nanovesicles for Delivery of MicroRNA Therapeutics

  • Boloix Amenós, Ariadna
  • Feiner-Gracia, Natalia
  • Repetto, Javier
  • Pascarella, Rosa
  • Soriano Fernández, Aroa
  • Masanas Jimenez, Marc
  • Roma Castanyer, Josep
  • Sánchez de Toledo Codina, Josep
  • Gallego Melcón, Soledad
  • Segura Ginard, Miguel
  • Foradada Felip, Laia
  • Köber, Mariana
Nanovesicles; Neuroblastoma; Pediatric cancer, Nanovesículas; Neuroblastoma; Cáncer pediátrico, Nanovesícules; Neuroblastoma; Càncer pediàtric, MicroRNAs (miRNAs) are small non-coding endogenous RNAs, which are attracting a growing interest as therapeutic molecules due to their central role in major diseases. However, the transformation of these biomolecules into drugs is limited due to their unstability in the bloodstream, caused by nucleases abundantly present in the blood, and poor capacity to enter cells. The conjugation of miRNAs to nanoparticles (NPs) could be an effective strategy for their clinical delivery. Herein, the engineering of non-liposomal lipid nanovesicles, named quatsomes (QS), for the delivery of miRNAs and other small RNAs into the cytosol of tumor cells, triggering a tumor-suppressive response is reported. The engineered pH-sensitive nanovesicles have controlled structure (unilamellar), size (<150 nm) and composition. These nanovesicles are colloidal stable (>24 weeks), and are prepared by a green, GMP compliant, and scalable one-step procedure, which are all unavoidable requirements for the arrival to the clinical practice of NP based miRNA therapeutics. Furthermore, QS protect miRNAs from RNAses and when injected intravenously, deliver them into liver, lung, and neuroblastoma xenografts tumors. These stable nanovesicles with tunable pH sensitiveness constitute an attractive platform for the efficient delivery of miRNAs and other small RNAs with therapeutic activity and their exploitation in the clinics., The funding was received by Ministerio de Educación, Cultura y Deporte (Grant no. FPU16/01099), Ministerio de Economía, Industria y Competividad (Grants MAT2016-80820-R, MAT2016-80826-R and SAF2016-75241-R), the Ministry of Science and Innovation (MINECO) of Spain through grant PID2019-105622RB-I00, from Instituto de Salud Carlos III (Grant no. CP16/00006, PI17/00564, PI20/00530, DTS20/00018) (Co-funded by European Regional Development Fund/European Social Fund) “Investing in your future”), from the EuroNanoMed II platform through the NanoVax project, from CIBER-BBN through grant TAG-SMARTLY, Joan Petit Foundation, Asociación Matem Lo Bitxo and Asociación Española Contra el Cáncer (Grant no. LABAE18009SEGU), as well as, Generalitat de Catalunya through the Centres de Recerca de Catalunya (CERCA) programme and grant no. 2017-SGR-918, and from Agency for Management of University and Research Grants (AGAUR) (Grant no 2018LLAV0064 and SIFECAT IU68-010017). Furthermore, ICMAB-CSIC acknowledges support from the MINECO through the Severo Ochoa Programme for Centres of Excellence in R&D (SEV-2015-0496 and CEX2019-000917-S).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Neuronal Differentiation-Related Epigenetic Regulator ZRF1 Has Independent Prognostic Value in Neuroblastoma but Is Functionally Dispensable In Vitro

  • Jimenez Jimenez, Carlos Gonzalo
  • Antonelli, Roberta
  • Masanas Jimenez, Marc
  • Soriano Fernández, Aroa
  • Devis-Jauregui, Laura
  • Camacho Soriano, Jessica
  • Magdaleno Cazon, Ainara
  • Hladun Alvaro, Raquel
  • Jubierre Zapater, Luz
  • Roma Castanyer, Josep
  • Sánchez de Toledo Codina, Josep
  • Moreno Martín-Retortillo, Lucas
  • Gallego Melcón, Soledad
  • Segura Ginard, Miguel
  • Guillén Burrieza, Gabriela
Epigenética; Diferenciación neuronal; Cáncer pediátrico, Epigenètica; Diferenciació neuronal; Càncer pediàtric, Epigenetics; Neuronal differentiation; Pediatric cancer, Neuroblastoma is a pediatric tumor of the peripheral nervous system that accounts for up to ~15% of all cancer-related deaths in children. Recently, it has become evident that epigenetic deregulation is a relevant event in pediatric tumors such as high-risk neuroblastomas, and a determinant for processes, such as cell differentiation blockade and sustained proliferation, which promote tumor progression and resistance to current therapies. Thus, a better understanding of epigenetic factors implicated in the aggressive behavior of neuroblastoma cells is crucial for the development of better treatments. In this study, we characterized the role of ZRF1, an epigenetic activator recruited to genes involved in the maintenance of the identity of neural progenitors. We combined analysis of patient sample expression datasets with loss- and gain-of-function studies on neuroblastoma cell lines. Functional analyses revealed that ZRF1 is functionally dispensable for those cellular functions related to cell differentiation, proliferation, migration, and invasion, and does not affect the cellular response to chemotherapeutic agents. However, we found that high levels of ZRF1 mRNA expression are associated to shorter overall survival of neuroblastoma patients, even when those patients with the most common molecular alterations used as prognostic factors are removed from the analyses, thereby suggesting that ZRF1 expression could be used as an independent prognostic factor in neuroblastoma., This work was funded by Instituto de Salud Carlos III (Grant no. CP16/00006, PI17/00564 and PI20/00530 to M.F Segura and MS17/00063 to D. Llobet-Navas); Asociación Española Contra el Cáncer (LABAE18009SEGU, LABAE19004LLOB); Generalitat de Catalunya AGAUR/European Social Fund (Grant no. 2017FI_B_00095 to C Jiménez); Asociación NEN; Joan Petit foundation; Asociación Pulseras Candela foundation; the #delhospitalalacatedral initiative led by Xavi Vallés; and the Rotary Clubs of Barcelona Eixample, Barcelona Diagonal, Santa Coloma de Gramanet, München-Blutenburg, Deutschland Gemeindienst, and others from Barcelona and its province.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Structural disruption of BAF chromatin remodeller impairs neuroblastoma metastasis by reverting an invasiveness epigenomic program

  • Jimenez Jimenez, Carlos Gonzalo
  • Antonelli, Roberta
  • Nadal-Ribelles, Mariona
  • Devis-Jauregui, Laura
  • Latorre Doménech, Pablo
  • Solé Serra, Carme
  • Masanas Jimenez, Marc
  • Molero Valenzuela, Adria
  • Soriano Fernández, Aroa
  • Sánchez de Toledo Codina, Josep
  • Llobet-Navas, David
  • Roma Castanyer, Josep
  • Posas, Francesc
  • de Nadal, Eulalia
  • Gallego Melcón, Soledad
  • Moreno Martín-Retortillo, Lucas
  • Segura Ginard, Miguel
Chromatin remodelling; Epigenetics; Metastasis, Remodelación de cromatina; Epigenética; Metástasis, Remodelació de cromatina; Epigenètica; Metàstasi, Background Epigenetic programming during development is essential for determining cell lineages, and alterations in this programming contribute to the initiation of embryonal tumour development. In neuroblastoma, neural crest progenitors block their course of natural differentiation into sympathoadrenergic cells, leading to the development of aggressive and metastatic paediatric cancer. Research of the epigenetic regulators responsible for oncogenic epigenomic networks is crucial for developing new epigenetic-based therapies against these tumours. Mammalian switch/sucrose non-fermenting (mSWI/SNF) ATP-dependent chromatin remodelling complexes act genome-wide translating epigenetic signals into open chromatin states. The present study aimed to understand the contribution of mSWI/SNF to the oncogenic epigenomes of neuroblastoma and its potential as a therapeutic target. Methods Functional characterisation of the mSWI/SNF complexes was performed in neuroblastoma cells using proteomic approaches, loss-of-function experiments, transcriptome and chromatin accessibility analyses, and in vitro and in vivo assays. Results Neuroblastoma cells contain three main mSWI/SNF subtypes, but only BRG1-associated factor (BAF) complex disruption through silencing of its key structural subunits, ARID1A and ARID1B, impairs cell proliferation by promoting cell cycle blockade. Genome-wide chromatin remodelling and transcriptomic analyses revealed that BAF disruption results in the epigenetic repression of an extensive invasiveness-related expression program involving integrins, cadherins, and key mesenchymal regulators, thereby reducing adhesion to the extracellular matrix and the subsequent invasion in vitro and drastically inhibiting the initiation and growth of neuroblastoma metastasis in vivo. Conclusions We report a novel ATPase-independent role for the BAF complex in maintaining an epigenomic program that allows neuroblastoma invasiveness and metastasis, urging for the development of new BAF pharmacological structural disruptors for therapeutic exploitation in metastatic neuroblastoma., This work was funded by Instituto de Salud Carlos III (CP16/00006, PI17/00564 and PI20/00530 to MFS and MS17/00063 to DL-N); Asociación Española Contra el Cáncer (LABAE18009SEGU to MFS, LABAE19004LLOB to DL-N, PROYE18010POSA to FP); Generalitat de Catalunya (2017FI_B_00095 to CJ, 2017SGR799 to FP and EdN; institutional funding through CERCA Programme); La Caixa Foundation (LCF/BQ/PR20/11770001 to MN-R); Spanish Ministry of Economy and Competitiveness (PID2021-124723NB-C21 to FP and PID2021-124723NB-C22 to EdN); Spanish Ministry of Science, Innovation and Universities (institutional funding through Centres of Excellence Severo Ochoa Award); State Research Agency (institutional funding through Unidad de Excelencia María de Maeztu, CEX2018-000792-M); and the Catalan Institution for Research and Advanced Studies (Academia awards to EdN and FP). Funding was also received from NEN association; Joan Petit foundation; Asociación Pulseras Candela foundation; and the Rotary Clubs of Barcelona Eixample, Barcelona Diagonal, Santa Coloma de Gramanet, München-Blutenburg, Deutschland Gemeindienst, and others from Barcelona and its province.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models

  • Masanas Jimenez, Marc
  • Masia Fandos, Nuria
  • Suarez Cabrera, Leticia
  • Olivan Riera, Mireia
  • Soriano Fernández, Aroa
  • Majem Cavaller, Blanca
  • Jimenez Jimenez, Carlos Gonzalo
  • Boloix Amenós, Ariadna
  • Toledano Martin, Ignasi
  • Navarro Jimenez, Alexandra
  • Sánchez de Toledo Codina, Josep
  • Roma Castanyer, Josep
  • Moreno Martín-Retortillo, Lucas
  • Gallego Melcón, Soledad
  • Segura Ginard, Miguel
  • Santamaria Margalef, Anna
  • Guillén Burrieza, Gabriela
Inhibidor de KIF11; Terapias dirigidas; Metástasis, Inhibidor de KIF11; Teràpies dirigides; Metàstasi, KIF11 inhibitor; Targeted therapies; Metastasis, In summary, our study provides a rationale for the future therapeutic integration in clinical trials of 4SC-205, an structurally distinct oral KIF11 inhibitor that shows potent antitumor activity in multiple preclinical neuroblastoma models and sensitizes neuroblastoma cells to standard chemotherapy and specific neuroblastoma-targeted therapies., The financial support for this research was provided by Instituto de Salud Calos III (PI20/00530 to Miguel F. Segura; PI20/01107 to Rosa Noguera; PI17/02248 and CPII18/00027 to Anna Santamaria; PI19/01320 to Alberto Villanueva); Ministerio de Educación, Cultura y Deporte (Grant no. FPU16/01099 to Marc Masanas). This work was also supported by the Asociación NEN (Nico contra el cancer infantil 2017–PVR00157).